For Ulcerative Colitis, Two First-In-Class Candidates and an Interleukin-23 Competition

February 01, 2023

A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.